https://www.sciencedaily.com/releases/2015/03/150316102028.htm
Patients taking evolocumab -- an investigational therapy previously shown to dramatically lower 'bad' cholesterol -- were half as likely to die, suffer a heart...
after one yearnew drugevolocumabcholesterolpatients